Repligen (RGEN) Total Non-Current Liabilities (2011 - 2026)
Repligen's (RGEN) quarterly Total Non-Current Liabilities came in at $808.6 million in Q1 2026, up 13.14% year-on-year from $714.7 million in Q1 2025, and up 14.24% on a QoQ basis from $707.7 million in Q4 2025.
Repligen (RGEN) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
Repligen (RGEN) has 16 years of Total Non-Current Liabilities data on file, last reported at $808.6 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 13.14% year-over-year to $808.6 million in Q1 2026; TTM through Mar 2026 was $808.6 million, a 13.14% increase from a year earlier, with the FY2025 full-year figure at $707.7 million, down 3.07% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $808.6 million, up from $707.7 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for RGEN reached as high as $808.6 million in Q1 2026 and fell as low as $170.1 million in Q3 2023.
- Historically, Total Non-Current Liabilities has averaged $508.1 million across 5 years, with a median of $705.6 million in 2024.
- Across the five-year window, Total Non-Current Liabilities retreated 21.54% in 2023 and surged 314.93% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $216.7 million in 2022, then soared by 223.67% to $701.4 million in 2023, then advanced by 4.1% to $730.2 million in 2024, then dropped by 3.07% to $707.7 million in 2025, then climbed by 14.24% to $808.6 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $808.6 million in Q1 2026, $707.7 million in Q4 2025, and $709.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | 6.48 Bn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | 1.92 Bn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | 48.37 Bn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | 17.13 Bn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | 941.16 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | 996.30 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | 4.24 Bn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | 8.65 Bn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | 2.06 Bn |
| 10 | Repligen | 7.75 Bn | 6.77 Bn | 108.28 Mn | 808.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 808.55 Mn |
| Dec 31, 2025 | 707.74 Mn |
| Sep 30, 2025 | 709.49 Mn |
| Jun 30, 2025 | 716.87 Mn |
| Mar 31, 2025 | 714.66 Mn |
| Dec 31, 2024 | 730.16 Mn |
| Sep 30, 2024 | 705.59 Mn |
| Jun 30, 2024 | 706.76 Mn |
| Mar 31, 2024 | 706.55 Mn |
| Dec 31, 2023 | 701.40 Mn |
| Sep 30, 2023 | 170.05 Mn |
| Jun 30, 2023 | 211.85 Mn |
| Mar 31, 2023 | 204.67 Mn |
| Dec 31, 2022 | 216.70 Mn |
| Sep 30, 2022 | 216.73 Mn |
| Jun 30, 2022 | 216.03 Mn |
| Mar 31, 2022 | 193.09 Mn |
| Dec 31, 2021 | 233.03 Mn |
| Sep 30, 2021 | 176.69 Mn |
| Jun 30, 2021 | 80.55 Mn |